Table S2.
Adenocarcinoma | Squamous cell carcinoma | Small cell carcinoma | Undiagnosed | |
---|---|---|---|---|
Patients, n | 9 | 4 | 3 | 5 |
Gender, female, n (%) | 1 (11.1) | 0 (0) | 1 (33.3) | 0 (0) |
Age, years | 70.8±8.4 | 76.5±6.2 | 72.0±7.5 | 76.6±4.6 |
Smoking index, pack-years | 61.6±20.0 | 65.9±28.5 | 48.2±14.0 | 78.1±49.2 |
Current smokers, n (%) | 0 (0) | 1 (25.0) | 0 (0) | 0 (0) |
Previous history of extra-pulmonary cancer, n (%) | 1 (11.1) | 1 (25.0) | 1 (33.3) | 2 (40.0) |
%FEV1 | 73.9±19.4 | 49.1±19.4 | 64.8±25.7 | 66.9±25.1 |
COPD grades 1/2/3/4, n | 4/3/2/0 | 0/3/0/1 | 1/1/1/0 | 2/1/2/0 |
Blood examination | ||||
Leukocytes, ×109/L | 7.3±1.6 | 6.8±2.1 | 9.2±0.3 | 6.4±0.7 |
CRP, mg/dL | 0.4±0.3 | 0.6±0.8 | 0.5±0.5 | 0.1±0.1 |
SAA/μg/mL | 12.0±11.1 | 16.3±12.4 | 33.4±23.8 | 75.6±129.1 |
CEA/ng/mL | 28.3±57.6 | 4.1±0.8 | 4.4±0.4 | 5.3±3.5 |
Pro-GRP/pg/mL | 45.5±9.9 | 51.8±19.2 | 73.4±7.3 | 102.7±32.7 |
CYFRA/ng/mL | 2.2±1.4 | 2.5±2.0 | 3.2±2.3 | 3.9±2.8 |
Clinical stage of NSCLC | ||||
I/II/III/IV/unknown, n | 6/0/2/1/0 | 1/1/1/1/0 | 3/0/0/0/2 | |
Clinical stage of SCLC LD/ED | 1/2 | |||
Location of primary mass | ||||
Upper/middle/lower lobes, n | 6/0/3 | 1/0/3 | 0/1/2 | 1/2/2 |
Diagnosis and annual follow-up | ||||
Chest CT/other extra causes, n | 8/1 | 4/0 | 1/2 | 4/1 |
Treatment | ||||
Operation/radiation/chemotherapy + radiation/chemotherapy/best supportive care, n | 5/0/1/2/1 | 0/1/0/2/1 | 0/0/0/3/0 | 0/1/0/0/4 |
Note: Data are presented as n, mean ± SD, or n (%).
Abbreviations: %FEV1, percent predicted forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; SAA, serum amyloid A; CEA, carcinoembryonic antigen; pro-GRP, pro-gastrin-releasing peptide; CYFRA, cytokeratin-19 fragments; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; LD, limited disease; ED, extensive disease; CT, computed tomography; SD, standard deviation.